INFECTIOUS ECONOMICS | by Blythe Adamson
LEARNING THE ECONOMICS OF INFECTIOUS DISEASES
The Flatiron study is proof of principle that real world evidence can be used to examine and inform health policy interventions, said Zafar, who led a discussion of Adamson’s study at the ASCO plenary session. Continue reading How to lead a research team from #hackathon to plenary in 6 months
Adamson spoke with Matthew Ong, a reporter with The Cancer Letter Before 2019, Blythe Adamson, a senior quantitative scientist at Flatiron Health, had never attended an annual meeting of the American Society of Clinical Oncology. In the shower, sometime in November 2018, Adamson came up with an idea for future research: “I think we should … Continue reading Q&A
This post has a summary of press coverage about results from a research study from Flatiron Health and Yale, following the Plenary Session presentation at ASCO 2019. We learned that Affordable Care Act (ACA) Medicaid expansion was associated with reduction in racial disparity in timely treatment of advanced cancer. Results were reported in the The … Continue reading Press: ACA Medicaid expansion eliminated racial disparities in timely cancer treatment
A new comprehensive landscape analysis of Medicaid health behavior incentive programs gathers together many challenges and potential solutions in the latest issue of Health Affairs. In 2017-2018 the team interviewed 80 key-informant stakeholders and searched the literature. The most common incentive type offered by programs was gift cards or vouchers, including cash, Visa gift cards, specific venue … Continue reading Incentivizing health-promoting behaviors
The Irish Department of Health (DoH) is in the process of developing a national biosimilar medicines policy which aims to increase biosimilar use by creating a robust framework where biologicals and biosimilars can be used safely, cost-effectively, and confidently in the health service. In this example from an Irish teaching hospital, the introduction of the biosimilar first to new patients, along with a switching study executed in parallel, helped to raise prescriber confidence. Continue reading data|evidence|policy|practice
@AcademyHealth #ARM2018 attendees: join me on Monday at 3:15 pm in room 605-606, where Anirban Basu will present our work in collaboration with the Patient Centered Outcomes Research Institute (PCORI) to quantify the potential economic impact of the findings from comparative-effectiveness research studies. Goal Our goal was to understand the potential benefits of implementing comparative-effectiveness … Continue reading Economic Impact of Comparative-Effectiveness Studies
While preparing a review for the journal Current HIV/AIDS Reports, I uncovered some interesting longitudinal trends in the care cascade and heterogeneity in the progress of US states. The following visualizations describe CDC HIV surveillance data from 2010-2014. They didn’t make the cut for our review paper, and they are too beautiful and interesting to … Continue reading Progress in viral suppression shifts distribution of metrics in US states
On Tuesday, April 17, the journal Nature Scientific Reports published our paper “Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study.” A few hours later, a reporter from BBC World Service reached out to discuss the the results of our study. Live Interview You can listen to this clip with … Continue reading BBC Interview
An Invitation Please join us at my doctoral dissertation defense titled “Mathematical Models to Evaluate the Clinical and Economic Impact of Biomedical HIV Prevention Strategies in the United States” at 12:30 pm on Thursday, May 3, 2018 at the Washington Research Foundation (WRF) Data Science Studio on the 6th floor of the Physics/Astronomy Tower at the University of Washington … Continue reading Doctoral Dissertation Defense
Failure to consider these methods could result in unintended consequences and exacerbate existing inequalities in health between patients who are “average” and “outliers.” Continue reading Why You Should Care About Person-Centered Treatment Effects
